Remote Patient Monitoring in Australia: What It Is, Medicare Coverage, and the U.S. Rollback Debate

Remote patient monitoring (RPM) is a digital health service where clinicians track patients’ vital signs or symptoms from home using connected devices. In Australia it can be part of Medicare-funded chronic disease management or privately billed through health insurers. The concept has grown rapidly worldwide, but a recent UnitedHealthcare decision to curtail U.S. coverage has sparked fresh controversy about the evidence base.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.

What is RPM

Key Takeaways

• RPM uses wearables, apps or dedicated hubs to collect health data.
• Australian Medicare reimburses RPM under chronic disease management plans.
• Evidence shows improved adherence and reduced hospital readmission for heart failure.
• U.S. insurers are pulling back despite mixed evidence.
• Consumers should verify device accuracy before enrolment.

Look, here's the thing - RPM isn’t just a fancy buzzword; it’s a concrete set of tools that let a nurse or GP see a patient’s blood pressure, glucose or oxygen saturation in real time, without the patient booking an appointment.

In my nine-year stint reporting on health policy (BA Journalism, UTS), I’ve watched RPM evolve from trial stages in Sydney’s western suburbs to a mainstream offering in private telehealth packages. The technology sits on three pillars:

1. Data capture. Wearables, Bluetooth-enabled oximeters, glucometers or even smart scales transmit readings to a cloud platform.
2. Clinical dashboards. Health providers log in to a secure portal, set thresholds, and get alerts when a reading drifts out of range.
3. Patient engagement. Apps remind users to take measurements, share trends, and sometimes deliver educational prompts.

The Australian Digital Health Agency reports that by mid-2024 more than 1.3 million Australians were using some form of remote monitoring, up from 600,000 in 2020. That surge aligns with the global AI in Telehealth & Telemedicine Market Report 2025-2030, which forecasts a compound annual growth rate of 22% for remote monitoring solutions.

Why is RPM important? Three fair-dinkum reasons:

• Access. Rural patients in places like Alice Springs can send a blood pressure reading to a specialist in Melbourne without the 1,600 km drive.
• Cost control. A 2023 Queensland Health audit showed RPM reduced heart-failure readmissions by 12%, saving an estimated AU$4.2 million in acute-care costs.
• Patient empowerment. When people see their own trends, they’re more likely to stick to medication and lifestyle plans.

That said, not every gadget lives up to the hype. Device validation studies published in the Australian Journal of General Practice warn that some Bluetooth-linked thermometers have a ±0.5°C margin of error, which can mislead clinicians monitoring infections.

Medicare RPM

Medicare in Australia, administered by Services Australia, covers RPM under the Chronic Disease Management (CDM) items 710 and 714. To qualify, a GP must create a CDM plan for a patient with a diagnosed chronic condition - such as type 2 diabetes, COPD, or heart failure - and then prescribe a remote monitoring service.

When I spoke to a practice nurse in Newcastle, she explained the workflow:

1. Patient’s condition is reviewed and an individualized CDM plan is documented.
2. The GP selects the RPM item (710 for measurement of vitals, 714 for comprehensive remote assessment).
3. The patient receives a validated device - often a Bluetooth blood pressure cuff linked to a clinic’s software.
4. Readings are uploaded automatically; the clinician reviews them weekly and may bill the item if at least three valid recordings are received.

Each RPM service attracts a standard Medicare rebate of AU$18.40 per patient per month (as of the 2024-25 schedule). Private health insurers often top this up with an additional AU$10-$15, especially for “health-hub” packages that bundle teleconsultations.

Contrast this with the UnitedStates scene: UnitedHealthcare announced on 1 January 2026 it would restrict RPM reimbursement, arguing there is “no evidence” that device-only programmes improve outcomes (Smart Meter Opinion Editorial). The move prompted a swift rebuttal from RPM Healthcare, which pointed to multiple peer-reviewed studies showing reduced emergency visits for chronic-ill patients (EIN Presswire). The Australian context is more cautious: the Therapeutic Goods Administration (TGA) requires manufacturers to prove accuracy, and the Medicare Benefits Schedule (MBS) only lists RPM as an adjunct to a clinician-led plan.

In my experience around the country, the biggest barrier isn’t the rebate - it’s the administrative load. A 2023 survey by the Royal Australian College of General Practitioners found that 68% of GPs felt RPM documentation was “time-consuming,” prompting some practices to outsource data review to third-party remote monitoring services.

Billing RPM

Billing for RPM in Australia is a blend of government rebates and private charges. Here’s a plain-spoken breakdown:

1. Medicare MBS items. Item 710 (BP/weight monitoring) and 714 (comprehensive review) are claimable once a CDM plan is in place.
2. Bulk-billing vs. co-pay. Some clinics bulk-bill the whole service; others ask a AU$5-$10 co-pay to cover device procurement.
3. Private insurer rebates. Major funds like Medibank and Bupa often apply a “mileage” rebate for home-based care - roughly AU$12 per month.
4. Device costs. A reputable Bluetooth cuff ranges from AU$80 to AU$150. Practices may lease the device, charging patients a nominal rental of AU$8-$12 per month.
5. Super-billing. For allied health providers (physiotherapists, dietitians) that integrate RPM into their care plan, separate super-billing codes exist, but they require a separate clinician-led assessment.

Below is a snapshot of typical monthly costs and reimbursements for a standard RPM programme for a patient with hypertension:

The arithmetic shows that, on paper, a fully reimbursed RPM episode can be profit-neutral for a practice, but only if the data are reviewed efficiently. The “hidden cost” is staff time - which is why many clinics adopt automated alert filters, a feature highlighted in the MarketsandMarkets telehealth forecast as a growth driver for 2026.

Evidence Debate

Here’s the thing - the UnitedHealthcare rollback was sparked by a claim that “there is no evidence” supporting low-engagement, device-only RPM. That line rings false to many of us on the ground. In Australia, the evidence base is nuanced but largely positive.

One landmark study published in The Medical Journal of Australia (2022) followed 2,014 heart-failure patients using Bluetooth scales and weight monitors. The intervention cut 30-day readmissions from 12% to 8% - a 33% relative reduction. The authors noted that the key was “clinician-triggered outreach” when weight spikes exceeded 2 kg.

Contrast that with the UnitedHealthcare policy paper, which lumped together “any RPM” without differentiating the “high-touch” models that include regular clinician review from “low-touch” devices that simply push data to a dashboard. A recent editorial in the Smart Meter Opinion stressed that downgrading reimbursement could force providers to strip away the human element, undermining the very outcomes that the data showed to be effective.

Legal experts highlighted in the ArentFox Schiff “Top Legal Challenges for the Health Care Industry in 2025” report that payer decisions to curtail RPM could expose insurers to breach-of-contract claims, especially where chronic-care management agreements explicitly reference remote monitoring as a service.

In Canada, a Frontiers article on remote monitoring trends points out that successful programmes pair technology with “clinical workflow integration,” mirroring what we see in Aussie pilots. The authors warn that isolated device distribution, like the model UnitedHealthcare seems to be rejecting, yields “limited health-system impact.”

So, while the U.S. saga illustrates how commercial decisions can outpace the evidence, in Australia the regulatory environment and Medicare guidelines insist on a clinician-led model, which is where the strong data live.

Bottom Line

Bottom line: RPM is a viable, evidence-backed component of chronic-disease care in Australia, but it works best when a qualified health professional actively reviews the data and acts on alerts. The UnitedHealthcare rollback in the United States serves as a cautionary tale - cutting funding for low-touch RPM can erode the clinical safety net, even if the technology itself is sound.

Our recommendation:

1. Ask your GP for a CDM-linked RPM plan. Ensure the service includes a regular clinician review, not just a device.
2. Verify device certification. Look for TGA-listed products and check that the supplier provides a clear data-security policy.
3. Track your own costs. Compare bulk-billed vs. co-pay models to avoid surprise charges.

In my experience, patients who stay engaged with a clinician-supported RPM programme report fewer hospital trips and a better sense of control over their health. If your insurer threatens to pull back coverage, remember that Medicare still backs RPM when tied to a chronic-disease plan - that’s the safety net we can rely on.

FAQ

Q: What does RPM stand for in health care?

A: RPM means Remote Patient Monitoring - a digital service where clinicians collect and review health data from a patient’s home using connected devices.

Q: Is RPM covered by Medicare in Australia?

A: Yes. Medicare reimburses RPM under Chronic Disease Management items 710 and 714, provided a GP-approved CDM plan is in place and at least three valid readings are submitted each month.

Q: How do I know if a remote monitoring device is reliable?

A: Look for TGA registration, check independent validation studies, and confirm the supplier offers secure data encryption. Faulty devices can give readings off by 0.5 °C or more.

Q: Why did UnitedHealthcare roll back RPM coverage?

A: UnitedHealthcare claimed there was “no evidence” that low-engagement, device-only RPM improved outcomes, prompting a January 2026 policy change. Critics argue the decision ignored studies showing benefit when clinician review is included.

Q: Can private insurers offer additional RPM rebates?

A: Many private funds, such as Medibank and Bupa, provide a supplementary rebate of around AU$10-$15 per month on top of the Medicare amount, especially for bundled telehealth packages.

Q: What are the main benefits of RPM for chronic disease?

A: RPM improves access for rural patients, helps reduce hospital readmissions, and empowers people to track their own health trends, leading to better medication adherence.